Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease

Abstract Background Active demethylation of 5-methyl-2′-deoxycytidine (5-mdC) in DNA occurs by oxidation to 5-(hydroxymethyl)-2′-deoxycytidine (5-hmdC) and further oxidation to 5-formyl-2′-deoxycytidine (5-fdC) and 5-carboxy-2′-deoxycytidine (5-cadC), and is carried out by enzymes of the ten-eleven...

Full description

Bibliographic Details
Main Authors: Tomasz Dziaman, Daniel Gackowski, Jolanta Guz, Kinga Linowiecka, Magdalena Bodnar, Marta Starczak, Ewelina Zarakowska, Martyna Modrzejewska, Anna Szpila, Justyna Szpotan, Maciej Gawronski, Anna Labejszo, Ariel Liebert, Zbigniew Banaszkiewicz, Maria Klopocka, Marek Foksinski, Andrzej Marszalek, Ryszard Olinski
Format: Article
Language:English
Published: BMC 2018-05-01
Series:Clinical Epigenetics
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13148-018-0505-0
id doaj-fd38b53e8df744ab9c03def9dba142b4
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Tomasz Dziaman
Daniel Gackowski
Jolanta Guz
Kinga Linowiecka
Magdalena Bodnar
Marta Starczak
Ewelina Zarakowska
Martyna Modrzejewska
Anna Szpila
Justyna Szpotan
Maciej Gawronski
Anna Labejszo
Ariel Liebert
Zbigniew Banaszkiewicz
Maria Klopocka
Marek Foksinski
Andrzej Marszalek
Ryszard Olinski
spellingShingle Tomasz Dziaman
Daniel Gackowski
Jolanta Guz
Kinga Linowiecka
Magdalena Bodnar
Marta Starczak
Ewelina Zarakowska
Martyna Modrzejewska
Anna Szpila
Justyna Szpotan
Maciej Gawronski
Anna Labejszo
Ariel Liebert
Zbigniew Banaszkiewicz
Maria Klopocka
Marek Foksinski
Andrzej Marszalek
Ryszard Olinski
Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
Clinical Epigenetics
DNA epigenetic modification
Ten-eleven translocation protein
Colon cancer
Inflammatory bowel disease
Adenoma
Demethylation
author_facet Tomasz Dziaman
Daniel Gackowski
Jolanta Guz
Kinga Linowiecka
Magdalena Bodnar
Marta Starczak
Ewelina Zarakowska
Martyna Modrzejewska
Anna Szpila
Justyna Szpotan
Maciej Gawronski
Anna Labejszo
Ariel Liebert
Zbigniew Banaszkiewicz
Maria Klopocka
Marek Foksinski
Andrzej Marszalek
Ryszard Olinski
author_sort Tomasz Dziaman
title Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
title_short Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
title_full Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
title_fullStr Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
title_full_unstemmed Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
title_sort characteristic profiles of dna epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
publisher BMC
series Clinical Epigenetics
issn 1868-7075
1868-7083
publishDate 2018-05-01
description Abstract Background Active demethylation of 5-methyl-2′-deoxycytidine (5-mdC) in DNA occurs by oxidation to 5-(hydroxymethyl)-2′-deoxycytidine (5-hmdC) and further oxidation to 5-formyl-2′-deoxycytidine (5-fdC) and 5-carboxy-2′-deoxycytidine (5-cadC), and is carried out by enzymes of the ten-eleven translocation family (TETs 1, 2, 3). Decreased level of epigenetic DNA modifications in cancer tissue may be a consequence of reduced activity/expression of TET proteins. To determine the role of epigenetic DNA modifications in colon cancer development, we analyzed their levels in normal colon and various colonic pathologies. Moreover, we determined the expressions of TETs at mRNA and protein level. The study included material from patients with inflammatory bowel disease (IBD), benign polyps (AD), and colorectal cancer (CRC). The levels of epigenetic DNA modifications and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) in examined tissues were determined by means of isotope-dilution automated online two-dimensional ultraperformance liquid chromatography with tandem mass spectrometry (2D-UPLC-MS/MS). The expressions of TET mRNA were measured with RT-qPCR, and the expressions of TET proteins were determined immunohistochemically. Results IBD was characterized by the highest level of 8-oxodG among all analyzed tissues, as well as by a decrease in 5-hmdC and 5-mdC levels (at a midrange between normal colon and CRC). AD had the lowest levels of 5-hmdC and 5-mdC of all examined tissues and showed an increase in 8-oxodG and 5-(hydroxymethyl)-2′-deoxyuridine (5-hmdU) levels. CRC was characterized by lower levels of 5-hmdC and 5-mdC, the lowest level of 5-fdC among all analyzed tissues, and relatively high content of 5-cadC. The expression of TET1 mRNA in CRC and AD was significantly weaker than in IBD and normal colon. Furthermore, CRC and AD showed significantly lower levels of TET2 and AID mRNA than normal colonic tissue. Conclusions Our findings suggest that a complex relationship between aberrant pattern of DNA epigenetic modification and cancer development does not depend solely on the transcriptional status of TET proteins, but also on the characteristics of premalignant/malignant cells. This study showed for the first time that the examined colonic pathologies had their unique epigenetic marks, distinguishing them from each other, as well as from normal colonic tissue. A decrease in 5-fdC level may be a characteristic feature of largely undifferentiated cancer cells.
topic DNA epigenetic modification
Ten-eleven translocation protein
Colon cancer
Inflammatory bowel disease
Adenoma
Demethylation
url http://link.springer.com/article/10.1186/s13148-018-0505-0
work_keys_str_mv AT tomaszdziaman characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT danielgackowski characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT jolantaguz characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT kingalinowiecka characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT magdalenabodnar characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT martastarczak characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT ewelinazarakowska characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT martynamodrzejewska characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT annaszpila characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT justynaszpotan characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT maciejgawronski characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT annalabejszo characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT arielliebert characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT zbigniewbanaszkiewicz characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT mariaklopocka characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT marekfoksinski characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT andrzejmarszalek characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT ryszardolinski characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
_version_ 1725378701225361408
spelling doaj-fd38b53e8df744ab9c03def9dba142b42020-11-25T00:17:38ZengBMCClinical Epigenetics1868-70751868-70832018-05-0110111110.1186/s13148-018-0505-0Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel diseaseTomasz Dziaman0Daniel Gackowski1Jolanta Guz2Kinga Linowiecka3Magdalena Bodnar4Marta Starczak5Ewelina Zarakowska6Martyna Modrzejewska7Anna Szpila8Justyna Szpotan9Maciej Gawronski10Anna Labejszo11Ariel Liebert12Zbigniew Banaszkiewicz13Maria Klopocka14Marek Foksinski15Andrzej Marszalek16Ryszard Olinski17Department of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Pathomorphology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Vascular Diseases and Internal Medicine, Faculty of Health Sciences, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Surgery, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Vascular Diseases and Internal Medicine, Faculty of Health Sciences, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Pathomorphology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunAbstract Background Active demethylation of 5-methyl-2′-deoxycytidine (5-mdC) in DNA occurs by oxidation to 5-(hydroxymethyl)-2′-deoxycytidine (5-hmdC) and further oxidation to 5-formyl-2′-deoxycytidine (5-fdC) and 5-carboxy-2′-deoxycytidine (5-cadC), and is carried out by enzymes of the ten-eleven translocation family (TETs 1, 2, 3). Decreased level of epigenetic DNA modifications in cancer tissue may be a consequence of reduced activity/expression of TET proteins. To determine the role of epigenetic DNA modifications in colon cancer development, we analyzed their levels in normal colon and various colonic pathologies. Moreover, we determined the expressions of TETs at mRNA and protein level. The study included material from patients with inflammatory bowel disease (IBD), benign polyps (AD), and colorectal cancer (CRC). The levels of epigenetic DNA modifications and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) in examined tissues were determined by means of isotope-dilution automated online two-dimensional ultraperformance liquid chromatography with tandem mass spectrometry (2D-UPLC-MS/MS). The expressions of TET mRNA were measured with RT-qPCR, and the expressions of TET proteins were determined immunohistochemically. Results IBD was characterized by the highest level of 8-oxodG among all analyzed tissues, as well as by a decrease in 5-hmdC and 5-mdC levels (at a midrange between normal colon and CRC). AD had the lowest levels of 5-hmdC and 5-mdC of all examined tissues and showed an increase in 8-oxodG and 5-(hydroxymethyl)-2′-deoxyuridine (5-hmdU) levels. CRC was characterized by lower levels of 5-hmdC and 5-mdC, the lowest level of 5-fdC among all analyzed tissues, and relatively high content of 5-cadC. The expression of TET1 mRNA in CRC and AD was significantly weaker than in IBD and normal colon. Furthermore, CRC and AD showed significantly lower levels of TET2 and AID mRNA than normal colonic tissue. Conclusions Our findings suggest that a complex relationship between aberrant pattern of DNA epigenetic modification and cancer development does not depend solely on the transcriptional status of TET proteins, but also on the characteristics of premalignant/malignant cells. This study showed for the first time that the examined colonic pathologies had their unique epigenetic marks, distinguishing them from each other, as well as from normal colonic tissue. A decrease in 5-fdC level may be a characteristic feature of largely undifferentiated cancer cells.http://link.springer.com/article/10.1186/s13148-018-0505-0DNA epigenetic modificationTen-eleven translocation proteinColon cancerInflammatory bowel diseaseAdenomaDemethylation